Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18764991 | 0.98 | POLB (0.70) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL31346128 | 0.89 | POLB (0.79) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7427658 | 0.89 | POLB (0.79) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL230157 | 0.88 | POLB (0.84) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL19025148 | 0.87 | POLB (0.83) | POLBNPC1RAB9ADDAH1CHRM1 | |
| Hydrochloric Acid SCHEMBL20532902 | 0.87 | POLB (0.77) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7006523 | 0.84 | POLB (1.00) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL119941 | 0.84 | DDAH1 (0.66) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7854448 | 0.84 | POLB (0.92) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7856311 | 0.82 | POLB (0.96) | POLBNPC1RAB9ADDAH1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2022-11-17 | — | — | US | disclosed |
| CN-114668761-A | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-108290878-B | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11066399-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-13 | — | — | US | disclosed |
| US-11001579-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-11 | — | — | US | disclosed |
| US-10738041-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2020-08-11 | — | — | US | disclosed |
| US-20190345151-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-11-14 | — | — | US | disclosed |
| US-4154844-A | ANTIHISTAMINE, GASTRIC JUICE ANTISECRETORY AGENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
| US-4151288-A | ANTHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-04-24 | — | — | US | disclosed |
| US-4137237-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4137234-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4070475-A | THIOALKYL-, AMINOALKYL-, AND OXYALKYL- SUBSTITUTED GUANIDINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-01-24 | — | — | US | disclosed |
| US-4024271-A | INHIBITORS OF HISTAMINE ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-17 | — | — | US | disclosed |
| US-4022797-A | PHARMACEUTICALS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-10 | — | — | US | disclosed |
| US-4018931-A | INHIBITION OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-04-19 | — | — | US | disclosed |
| US-3950353-A | HISTAMINE INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
| US-3950333-A | HISTAMINE INHIBITORS, OXYALKYL, THIOALKYL, AMINOALKYL DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345151-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | POLB 4246/4885NPC1 445/4885RAB9A 2934/4885 |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | POLB 4246/4885NPC1 445/4885RAB9A 2934/4885 |
| US-10738041-B2 | Ferroportin inhibitors | SLC40A1, HAMP, TFRC | POLB 2941/4885NPC1 193/4885RAB9A 2727/4885 |
| US-11066399-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | POLB 3917/4885NPC1 414/4885RAB9A 3011/4885 |
| US-11001579-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | POLB 3917/4885NPC1 414/4885RAB9A 3011/4885 |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | POLB 4246/4885NPC1 445/4885RAB9A 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.